ArticleCureus2026
Triple-Negative Breast Cancer in Pregnancy: A Case Report and Narrative Review of Multidisciplinary Management in a Resource-Limited Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy-associated breast cancer is an uncommon clinical entity, and management is particularly challenging when associated with triple-negative breast cancer (TNBC) because of its aggressive biology and limited targeted treatment options. We report a case of a 35-year-old gravida 2, para 1 female diagnosed with TNBC at 19 weeks' gestation, following a spontaneous conception after 12 years of subfertility. She presented with a progressively enlarging left breast and axillary mass. Imaging demonstrated a BI-RADS (Breast Imaging Reporting and Data System) 5 lesion, and core biopsy of the axillary lesion confirmed metastatic carcinoma with a triple-negative, high-proliferation-index immunophenotype (CK7+, GATA3+) supporting a breast primary. Staging with abdominal ultrasound and brain MRI showed no evidence of distant disease, and she was staged as clinical T2N1M0. Following multidisciplinary team discussion, neoadjuvant chemotherapy with epirubicin and cyclophosphamide was initiated at 19 weeks' gestation, administered as four cycles on a standard three-weekly schedule, before transitioning to weekly paclitaxel from 30 weeks' gestation. Maternal tolerance during the antenatal treatment course was satisfactory, and serial fetal surveillance (biometry, amniotic fluid assessment, and biophysical profile) remained reassuring throughout. Delivery by elective caesarean section was planned at 34 weeks' gestation, with definitive breast and axillary surgery deferred to the postpartum period. This case illustrates that guideline-concordant multidisciplinary chemotherapy administration is feasible during pregnancy, including in a resource-limited setting. As this report focuses on the antenatal diagnostic and treatment course, definitive delivery, neonatal, and postpartum oncologic outcome data were not available for inclusion and are acknowledged as a limitation. This report nonetheless contributes to the limited clinical literature on TNBC diagnosed during pregnancy, particularly from a resource-limited, non-tertiary setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.